CRYO CELL INTERNATIONAL INC
For the period ended Aug 31, 2026. Filed Oct 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 31, 2026 · Filed Oct 9, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-05-31; filed 2026-07-15.
0001193125-26-304834
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2026-08-31; filed 2026-10-09.
0001193125-26-419156
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 8 previous paragraphs and 6 current paragraphs.
6 unchanged; 0 reworded; 0 added; 2 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Removed paragraphs (2)
Previous report
The Company may not regain compliance with the continued listing requirements.
Previous report
The Company submitted the Plan of Compliance to the NYSE American. The NYSE American accepted the Company’s Plan on May 6, 2026 and granted the Company an extension of time until September 9, 2027 to regain compliance. During the plan period, the Company’s common stock will continue to be listed and traded on NYSE American, subject to the Company’s compliance with the initiatives and conditions set forth in the compliance plan and continued periodic review by NYSE. If the Company is not in compliance with the continued listing standards by September 9, 2027, or if the Company does not make progress consistent with the plan during the plan period, the Company will be subject to delisting procedures as set forth in the NYSE American Company Guide. There can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing standards within the required timeframe.